Assembly Biosciences, Inc.
ASMB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 12.1% | 2.2% | 28% | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 100% | -67.5% | 100% | -94.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -84.9% | -114.9% | -105.2% | -156.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -85.2% | -105.9% | -93.6% | -140.5% |
| EPS Diluted | -1.2 | -1.33 | -1.17 | -1.72 |
| % Growth | 9.8% | -13.7% | 32% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |